《美股業績》新冠疫苗庫存減值 莫德納上季盈轉虧36億美元
莫德納(MRNA.US)公布,由於與稅收減免和減少新冠疫苗生產相關的31億美元非現金費用,第三季虧損36.3億美元,每股虧損9.53美元,去年同期純利10.4億美元。
期內,收入為18.3億美元,高於預期的14億美元。當中,新冠疫苗銷售額按年下跌44%。
公司重申目前全年新冠疫苗銷售額至少60億美元的預期,又預計明年收入將下跌至約40億美元,主要由於針對呼吸道合胞病毒(RSV)的新疫苗上市,低於分析師預計的60億美元。
周四盤前交易中,莫德納股價下跌超過15%。截至周三收盤,莫德納的股價年內下跌超過57%,其市值約為290億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.